Up-regulation of platelet activation in hemophilia A

Haematologica

Volumn 96, Issue 6, 2011, Pages 888-895

  van Bladel, Esther R ^a   Roest, Mark ^a   de Groot, Philip G ^a   Schutgens, Roger E G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Activation; FVIII consumption; Hemophilia A; Platelets; Up regulation

Indexed keywords

BLOOD CLOTTING FACTOR 8; CHEMOKINE; PADGEM PROTEIN; PROTEIN CXCL7; RANTES; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEMOPHILIA A; HUMAN; HUMAN CELL; MALE; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; BLOOD PLATELETS; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 79958068477     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042663     Document Type: Article

References (11)

1. den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia. 2009;15(1):83-90.
2. Biggs R, Macfarlane RG. Haemophilia and related conditions: a survey of 187 cases. Br J Haematol. 1958;4(1):1-27.
3. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
4. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236(4): 391-9.
5. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia. 2000; 6(1):23-32.
6. van Dijk K, van der Bom JG, Fischer K, de Groot PG, van den Berg HM. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost. 2007;5(5):1062-4.
7. van Dijk K, van der Bom JG, Lenting PJ, de Groot PG, Mauser-Buschoten EP, Roosendaal G, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005;90(4):494-8.
8. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-49.
9. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996;88(8):2951-8.
10. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CLJJ, Sixma JJ, van den Berg HM. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost. 2000;83(1):65-9.
11. Fijnvandraat K, Peters M, ten Cate JW. Interindividual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol. 1995;91(2):474-6.